NCT02046083 (PITA 3) is a Phase 2/Phase 3 clinical trial of arachid in Peanut Allergy, sponsored by University Hospital, Clermont-Ferrand.

Who is sponsoring NCT02046083?

NCT02046083 is sponsored by University Hospital, Clermont-Ferrand.

What drugs are being tested in NCT02046083?

Interventions in NCT02046083: arachid.

What condition does NCT02046083 study?

NCT02046083 studies Peanut Allergy.

Is NCT02046083 still recruiting?

NCT02046083 is currently status unknown. Last updated 23 January 2014.

Last reviewed 2014-01-23 · How we verify

NCT02046083: PITA 3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers

Status unknown Phase 2/Phase 3 Last updated 23 January 2014

What this trial tests

Phase 2/Phase 3 trial testing arachid in Peanut Allergy in 60 participants. Status unknown.

Timeline

1 July 2013

Primary endpoint
1 January 2017

1 January 2017

Quick facts

Lead sponsor	University Hospital, Clermont-Ferrand
Phase	Phase 2/Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 July 2013
Primary completion	1 January 2017
Estimated completion	1 January 2017
Sites	1 location across France

Drugs / interventions tested

arachid — full drug profile →

Conditions studied

Peanut Allergy — all drugs for Peanut Allergy →

Sponsor

University Hospital, Clermont-Ferrand

Who can join

Adults 12 to 18, any sex, with Peanut Allergy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of patients which tolerate the cumulative dose of 2 grams of peanut at the end of the first phase of 24 weeks between treatment and placebo groups
Time frame: at 24 weeks

Sponsor's own description

The primary purpose of the protocol is to evaluate the efficacy of a protocol for induction of tolerance to peanut ingestion increasing doses. The secondary purpose is to determine the interest of a prolonged maintenance therapy

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Approaches in the Inhibition of IgE-Induced Mast Cell Reactivity in Food Allergy.
Tontini C, Bulfone-Paus S. · · 2021 · cited 24× · PMID 34456900 · DOI 10.3389/fimmu.2021.613461
From Allergen Molecules to Molecular Immunotherapy of Nut Allergy: A Hard Nut to Crack.
Fuhrmann V, Huang HJ, Akarsu A, Shilovskiy I, et al · · 2021 · cited 21× · PMID 34630424 · DOI 10.3389/fimmu.2021.742732
Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial.
Michaud E, Evrard B, Pereira B, Rochette E, et al · · 2015 · cited 4× · PMID 25925398 · DOI 10.1186/s13063-015-0717-y

Verify or expand the search:

Other recruiting trials for Peanut Allergy

Currently open trials in the same condition.

NCT07349212 — UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies · Phase 1, PHASE2 · recruiting
NCT05695261 — Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients · Phase 2 · recruiting
NCT05503446 — Using Commonly Available Food Products To Treat Food Allergy · NA · active not recruiting
NCT05667610 — Immune-supportive Diet and Gut Permeability in Allergic Children · NA · recruiting
NCT06256146 — Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety · NA · recruiting

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02046083 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
Last refreshed: 23 January 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02046083.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing